Consider buying Ultragenyx Pharmaceutical (RARE) as an undervalued growth play with potential acquisition upside targeting $30 to $40. Buy Bloom Energy (BE) to benefit from rising AI power infrastructure demand, and accumulate Micron Technology (MU) for long-term semiconductor upside toward $1,050 to $1,500. Treat recent price dips in Meta Platforms (META) as high-conviction buying opportunities supported by robust underlying fundamentals. Short IonQ (IONQ) around $39 due to unproven commercial viability in quantum computing, along with Pfizer (PFE) amid severe drug pipeline headwinds. Lock in profits on recent price surges in Advanced Micro Devices (AMD), while strictly avoiding toxic microcaps like QCLS that face severe dilution risks.

Ultragenyx Pharmaceutical (RARE)

• The speaker maintains a significant long position, describing the stock as deeply undervalued ("so cheap, it's crazy").
  • The company recently received FDA approval for a rare disease gene therapy (Sanfilippo treatment).
  • CEO Emil Kakkis is noted to have an exceptional track record navigating FDA approvals.
  • The stock is viewed as a potential long-term acquisition target (with BioMarin mentioned as a potential suitor), with potential price targets mentioned around $30 to $40.

Takeaways

• Bullish outlook driven by strong rare disease drug pipeline execution, regulatory approvals, and potential buyout upside.

Micron Technology (MU)

• The stock saw strong upward momentum, surging toward $975–$980.
  • While positions were trimmed slightly early, the broader semiconductor sector is viewed as having significant room to run.
  • Potential long-term upside targets mentioned include $1,050, $1,100, and up to $1,500, though macro volatility remains an unpredictable variable.

Takeaways

• Favorable long-term bias toward memory and semiconductor hardware; preferred stance is long rather than short despite short-term pullbacks.

Nebius Group (NBIS)

• Actively shorted during the session following an announcement of cloud price increases.
  • The price hike was viewed as a consensus, lagging move rather than a competitive advantage, as the rest of the industry had already raised prices.
  • The trade yielded substantial fast gains as the stock plummeted on the market open.

Takeaways

• Bearish stance when companies release expected or late pricing adjustments that the market has already priced in.

IonQ (IONQ)

• Maintained as an active short position around $39.
  • Highly skeptical of the company's technology, referring to it as unproven and labeling quantum computing claims as marketing rather than substance.
  • A recent press release touting a 15% improvement in quantum metrics was dismissed as unconvincing.

Takeaways

• Bearish outlook on high-valuation quantum computing pure-plays lacking near-term commercial viability.

Bloom Energy (BE)

• Highlighted as a standout long performer benefiting from the AI infrastructure boom.
  • The company manufactures fuel cells that provide critical on-site power and backup solutions for energy-intensive AI data centers.

Takeaways

• Bullish play on the secondary AI trade: power generation and energy infrastructure for data center scaling.

Pfizer (PFE)

• Identified as an active short position.
  • Described as facing one of the most challenging operating and pipeline environments in the large-cap biopharma sector.

Takeaways

• Bearish sentiment on large-cap pharma names struggling with patent cliffs and lack of near-term pipeline catalysts.

Meta Platforms (META)

• Stated a strong long bias toward the company, viewing recent price weakness as an attractive buying opportunity.

Takeaways

• Bullish stance on dips; favored mega-cap tech holding with strong fundamentals.

Advanced Micro Devices (AMD)

• Surged 7% to 10% intraday following reports of passing along 10% chip price increases driven by rising TSMC (TSM) manufacturing costs.
  • Despite momentum, Martin notes historical difficulty trading the name and suggests taking profits after large mega-cap run-ups.

Takeaways

• Positive momentum supported by pricing power, but caution is warranted regarding chasing extended rallies.

Microcap / Structured Finance Warning (QCLS)

• Detailed an exit from a previous executive/advisory role resulting in an approximate 80% loss.
  • The company's capital structure is burdened by anti-dilutive preferred shares and "triple-ratchet warrants," which continuously adjust strike prices downward upon any new financing, effectively diluting common stockholders toward zero.
  • Warns that certain PIPE (Private Investment in Public Equity) funds profit by shorting common stock against their warrant hedges.

Takeaways

• Extreme risk warning: Avoid microcap companies with toxic convertible debt, preferred structures, or ratchet warrants, as common shareholders bear all dilution risk.